🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hossein Borghaei

Fox Chase Cancer Center

ORCID: 0000-0002-2577-4454

Also affiliated with Temple University Health System, University of Pennsylvania

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial”.

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Nature Medicine(2021)10.1038/s41591-021-01541-0

N/A

3.9DataRank · unranked

137 citations

Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs +22 more

Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)

Lung Cancer(2021)10.1016/j.lungcan.2021.08.010

N/A

0.416DataRank · unranked

15 citations

Mohammad Asad, Mohammed Najeeb Al Hallak, Md. Hafiz Uddin, Ammar Sukari, Yasmine Baca +18 more

Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.07.024

N/A

0.326DataRank · unranked

5 citations

Xing Hua, Michael C. Wu, Khaled Tolba, Saiama N. Waqar, Konstantin H. Dragnev +10 more

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

Cancers(2021)10.3390/cancers13133164

N/A

0DataRank · unranked

63 citations

Sushma Jonna, Alexander Y. Deneka, Jyoti D. Patel, Mohamed E. Abazeed, Erica A. Golemis +3 more

Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)

Oncogenesis(2021)10.1038/s41389-021-00317-y

N/A

0DataRank · unranked

37 citations

Igor Bychkov, Bulat Faezov, Alexander Y. Deneka, Alexander E. Kudinov, Émmanuelle Nicolas +18 more

175P Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2899

N/A

0DataRank · unranked

1 citations

Fenghai Duan, Vidya Sankar Viswanathan, Mohammadhadi Khorrami, Ning An, Vamsidhar Velcheti +7 more

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9035

N/A

0DataRank · unranked

0 citations

Mary W. Redman, David Kozono, Sam Callis, Hanna Tukachinsky, Khaled Tolba +14 more

Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels

Lung Cancer(2024)10.1016/j.lungcan.2024.107510

N/A

0DataRank · unranked

28 citations

Elizabeth A. Handorf, Yunyun Zhou, Hossein Borghaei, Charu Aggarwal, Jessica R. Bauman +1 more

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100755

N/A

0DataRank · unranked

4 citations

Yunyun Zhou, Elizabeth A. Handorf, Hossein Borghaei, Jessica R. Bauman, Charu Aggarwal +1 more

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer(2020)10.1002/cncr.33142

N/A

0DataRank · unranked

111 citations

Corey J. Langer, Luis Paz‐Ares, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino +8 more

Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer

The Oncologist(2024)10.1093/oncolo/oyad335

N/A

0DataRank · unranked

2 citations

Yating Wang, Suresh S. Ramalingam, Sheena Bhalla, Zhuoxin Sun, Hossein Borghaei +3 more

Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.06.025

N/A

0DataRank · unranked

53 citations

Xiaofei Wang, Lin Gu, Stephanie Q. Duong, Thomas E. Stinchcombe, Robert A. Kratzke +4 more

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.10.015

N/A

0DataRank · unranked

11 citations

Mary W. Redman, Karen Kelly, S. Waqar, Francisco Robert, Gauri Kiefer +6 more